Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LAB 
Standard Biotools Inc (LAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: LAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.77
1 Year Target Price $1.77
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.83% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 485.13M USD | Price to earnings Ratio - | 1Y Target Price 1.77 |
Price to earnings Ratio - | 1Y Target Price 1.77 | ||
Volume (30-day avg) 3 | Beta 1.31 | 52 Weeks Range 0.92 - 2.32 | Updated Date 10/19/2025 |
52 Weeks Range 0.92 - 2.32 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -69.95% | Operating Margin (TTM) -29.42% |
Management Effectiveness
Return on Assets (TTM) -13.62% | Return on Equity (TTM) -29.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 280484730 | Price to Sales(TTM) 2.82 |
Enterprise Value 280484730 | Price to Sales(TTM) 2.82 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA -19.22 | Shares Outstanding 381995102 | Shares Floating 48217174 |
Shares Outstanding 381995102 | Shares Floating 48217174 | ||
Percent Insiders 2.66 | Percent Institutions 72.98 |
Upturn AI SWOT
Standard Biotools Inc
Company Overview
History and Background
Standard BioTools Inc. (formerly Fluidigm) was founded in 1999. It focuses on developing and manufacturing instruments and consumables for single-cell biology, proteomics, and genomics. Significant milestones include IPO and subsequent acquisitions to expand its product portfolio.
Core Business Areas
- Mass Cytometry: Provides instruments and reagents for single-cell protein analysis using mass cytometry technology (CyTOF). This allows for high-parameter analysis of individual cells, essential for immunology and cancer research.
- Microfluidics: Offers microfluidic-based solutions for genomics and proteomics, enabling efficient and precise sample processing and analysis.
- Imaging Mass Cytometry: Provides instruments for spatially resolved, highly multiplexed tissue analysis using imaging mass cytometry technology (Hyperion).
Leadership and Structure
The company is led by a CEO and a management team responsible for different functional areas (e.g., R&D, sales, marketing). It has a board of directors that oversees the company's strategy and performance.
Top Products and Market Share
Key Offerings
- Helios Mass Cytometer: A high-parameter single-cell protein analysis platform using mass cytometry. Competitors include BD Biosciences, Miltenyi Biotec. Market share information is difficult to pinpoint, but estimated to be in a similar range to competitors.
- Hyperion Imaging System: An imaging mass cytometry system for spatially resolved tissue analysis. Competitors include Akoya Biosciences, RareCyte. Market share information is difficult to pinpoint, but estimated to be in a similar range to competitors.
Market Dynamics
Industry Overview
The life science tools industry is characterized by innovation and technological advancements in genomics, proteomics, and cell biology. There is a growing demand for single-cell analysis and high-throughput technologies.
Positioning
Standard BioTools is positioned as a provider of advanced tools for single-cell and tissue analysis. Their competitive advantage lies in their CyTOF and imaging mass cytometry technologies that offer high-parameter and spatially resolved analysis capabilities.
Total Addressable Market (TAM)
The TAM for single-cell and tissue analysis is estimated to be in the billions of USD. Standard BioTools aims to capture a significant share of this market with its specialized products and technologies.
Upturn SWOT Analysis
Strengths
- Proprietary CyTOF technology
- Strong expertise in microfluidics
- Established customer base in research institutions
- High-parameter single-cell analysis capabilities
Weaknesses
- Limited financial resources relative to larger competitors
- Market acceptance depends on novel technology adoption
- Reliance on specialized equipment
- Smaller sales/marketing footprint
Opportunities
- Growing demand for single-cell analysis
- Expanding applications in cancer research and immunology
- Potential for partnerships with pharmaceutical companies
- Increased adoption of imaging mass cytometry
Threats
- Competition from larger companies with more resources
- Technological disruption from new analysis methods
- Economic downturn affecting research funding
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- DHCN
- AKYA
Competitive Landscape
Standard BioTools faces stiff competition from larger, more established players in the life science tools industry. Their competitive advantage lies in their CyTOF technology and imaging mass cytometry, but they need to address their financial challenges and market acceptance to compete effectively.
Major Acquisitions
DVS Sciences
- Year: 2014
- Acquisition Price (USD millions): 200
- Strategic Rationale: To acquire mass cytometry technology and expand product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been volatile due to market conditions and company-specific challenges.
Future Projections: Future growth is dependent on the successful execution of the company's restructuring plan and adoption of its products by researchers.
Recent Initiatives: Recent initiatives include cost reduction measures, streamlining operations, and focusing on core product lines.
Summary
Standard BioTools has valuable technology but faces challenges including financial instability and strong competition. Successful restructuring and increased market adoption of their core products are crucial for future success. The company needs to manage its cash flow effectively and differentiate itself in a crowded market. It must capitalize on emerging opportunities in single-cell and tissue analysis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimations and industry reports, and may not be precise. Financial information is based on past performance and is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Standard Biotools Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2003-07-29 | President, CEO & Director Dr. Michael Egholm Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 814 | Website https://www.standardbio.com |
Full time employees 814 | Website https://www.standardbio.com | ||
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.